Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2026-08-12 16:16:51 ET · period of report 2026-08-10 · accession 0001992352-26-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2026-08-12 16:16	2026-08-10	REGN	Guarini Kathryn	Dir	M - OptEx	$719.37	+400	1,003	+66%	+$287.7K
DT	2026-08-12 16:16	2026-08-10	REGN	Guarini Kathryn	Dir	S - Sale+OE	$800.00	-400	603	-40%	-$320.0K
DT	2026-08-12 16:16	2026-08-10	REGN	Guarini Kathryn	Dir	M - OptEx	$0.00	-400	1,558	-20%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-08-10	M	A	400	$719.37	1,003	D	—	—	(F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
2	Common	Common Stock	2026-08-10	S	D	400	$800.00	603	D	—	—	(F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
3	Derivative	Non-Qualified Stock Option (right to buy)	2026-08-10	M	D	400	$0.00	1,558	D	$719.37 · — to 2035-01-02	400 Common Stock	(F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. (F2) On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.